Dr Tony Holohan getting married to girlfriend Ciara Cronin next week
Dr Holohan, who chaired the National Public Health Emergency Team (Nepht) during the Covid-19 pandemic, shared the news on his social media
Former chief medical officer Dr Tony Holohan has announced he is getting married in one week to girlfriend Ciara Cronin.
Dr Holohan, who chaired the National Public Health Emergency Team (Nepht) during the Covid-19 pandemic, shared the news on his social media.
Dr Holohan shared a photo of the pair walking in Dun Laoghaire, with the caption: 'One week to go to our big day. I'm so happy that Ciara and I will spend the rest of our lives together.'
We need your consent to load this Social Media content. We use a number of different Social Media outlets to manage extra content that can set cookies on your device and collect data about your activity.
Please review your details and accept them to load the content
In his memoir, We Need To Talk, released in 2023, Dr Holohan opened up about the death of his first wife Dr Emer Holohan, who died in 2021 following a diagnosis of multiple myeloma nine years prior.
She was a specialist in public health medicine and a medical graduate of UCD.
In the memoir, Dr Holohan had revealed he is now in a 'lovely' relationship with psychotherapist Ciara Cronin.
He also criticised the Government's decision to reopen hospitality in late 2020 for a 'meaningful Christmas'. During the pandemic, the National Public Health Emergency Team exercised major control over recommendations around lockdowns, freedoms such as how far people could exercise outside their home, as well as the closure of schools and hospitality.
Dr Tony Holohan and Ciara Cronin.
News in 90 Seconds - 3rd June 2025
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Sunday World
3 hours ago
- Sunday World
UAE Minister issues statement after extradition of Kinahan chief Sean McGovern
'This positive development is further evidence of the excellent criminal justice cooperation between the governments of the UAE and Ireland' McGovern was flown by the Irish Air Corps from Dubai and brought to court in Dublin under Garda escort The minister for justice in the United Arab Emirates has hailed the police forces of both countries following the recent extradition of Kinahan chief Sean McGovern to Ireland. Abdullah bin Sultan Al Nuaimi and Minister of Justice Jim O'Callaghan spoke by phone following the extradition of the Irish national, who is accused of murder and involvement in a criminal organisation. It followed a decision issued by the Dubai Court of Cassation after McGovern had spent eight months in prison in Dubai. According to a statement issued by the UAE, both ministers emphasised that the extradition underscores a firm and ongoing joint commitment to upholding the rule of law and fostering international cooperation. 'It reflects the strong relationship between the UAE and Ireland, our continued collaboration in the pursuit of international justice and a shared determination to ensure that justice is served,' the statement reads. 'This positive development is further evidence of the excellent criminal justice cooperation between the governments of the UAE and Ireland and highlights our joint dedication to ensuring that criminal prosecutions may be brought against those who attempt to evade justice.' Both ministers commended the Dubai Police and gardai 'for their ongoing engagement and commitment to enhancing police-to-police cooperation, recognising their vital role in joint efforts to combat the global threat of organised crime'. 'The two sides emphasised the importance of continued collaboration and joint initiatives between their respective police agencies to promote security, uphold the rule of law, and safeguard justice across borders.' McGovern was flown by the Irish Air Corps from Dubai and brought to court in Dublin under Garda escort Senior Kinahan gang member McGovern is back in Ireland after what has been described as a 'complicated and secretive' extradition process. Gardaí believed he was being returned home on a couple of other occasions in recent months, only for legal issues to arise at the last minute. The 39-year-old Dubliner is one of cartel leader Daniel Kinahan's closest confidants. The leadership of the Kinahan cartel, including Daniel, his father Christy Sr and brother Christopher Jr, remain in Dubai. The Kinahans are 'not panicking' over McGovern's extradition and 'have no plans to flee Dubai', according to garda intelligence. 'They've no plans to flee, and if they did, we would be able to find them because of international co-operation,' a source said. Sean McGovern News in 90 Seconds - 5th June 2025 Gardaí are awaiting a direction from the DPP on whether Daniel Kinahan and other members of his family should face a range of criminal charges, including leadership of an organised crime gang. The state prosecutor has been considering an extensive garda file on Daniel Kinahan and other senior cartel members for two years. 'It could be a good sign there is no direction yet. It means the DPP is very thoroughly looking at it,' the source said. As first reported in the Sunday World last year, the proposed extradition of McGovern was seen as a 'test case' for plans to eventually attempt to return Daniel Kinahan to Ireland to face charges. The source pointed out that navigating the extradition process for McGovern would prove 'very helpful' if gardaí make attempts to extradite Daniel Kinahan. 'The extradition process for Sean McGovern was challenging. Due process had to take place, which meant a lot of legal issues had to be overcome,' the source said. A good relationship was developed with authorities in the United Arab Emirates and there was a significant amount of help from Interpol on this case too, but it was a secretive process and very different to our own.' It is understood gardaí did not receive regular updates on developments in Dubai in relation to McGovern's planned extradition and instead 'had to trust the process'. Meanwhile, the father-of-two's journey home on a military aircraft that made a number of stops en route passed off without incident. McGovern's partner and the mother of his two children is expected to return to Ireland from Dubai. McGovern, formerly of Kildare Road, Crumlin, is the most senior member of the Kinahan crime group to be charged before the Irish courts. He appeared in the Special Criminal Court last Thursday evening, shortly after arriving in Ireland. He is charged with the murder of Noel Kirwan (62) at St Ronan's Drive, Clondalkin, Dublin, on December 22, 2016. Kirwan was shot dead as he sat in his car with his partner in the driveway of her home. He was not involved in the feud, but was targeted after being spotted beside Gerry 'The Monk' Hutch at a funeral. McGovern is also charged with directing a criminal organisation involved in the conspiracy to murder a rival gangster. The alleged offences were carried out as part of the Hutch-Kinahan feud, which claimed up to 18 lives in Ireland and abroad.
Sunday World
4 hours ago
- Sunday World
Tommy Robinson to appear in court charged with harassing two journalists
The 42-year-old will appear at Westminster Magistrates' Court on Thursday, facing charges over his alleged conduct towards two Daily Mail reporters Tommy Robinson was jailed at Woolwich Crown Court last October after admitting 10 breaches of a High Court order made in 2021 (Jordan Pettitt/PA) Political activist Tommy Robinson is due to appear in court charged with harassing two journalists. The 42-year-old, whose real name is Stephen Yaxley-Lennon, is set to appear at Westminster Magistrates' Court on Thursday to face charges over his alleged conduct towards two Daily Mail reporters. He is accused of two counts of harassment causing fear of violence between August 5 and 7 2024. Robinson, from Luton, Bedfordshire, was released from prison on May 27 after serving a jail term for the civil offence of contempt of court. He was jailed in October after admitting multiple breaches of an injunction made in 2021, which barred him from repeating false allegations against a Syrian refugee who successfully sued him for libel. The activist left HMP Woodhill after his 18-month sentence was reduced by four months at the High Court. He was filmed speaking on his X social media channel for around 20 minutes with longer hair and a bushy beard, and wearing a rosary around his neck, as he left the prison. Robinson is facing a separate trial in October next year over an accusation that he failed to provide the Pin for his mobile phone when stopped by Kent Police in Folkestone in July 2024. Tommy Robinson was jailed at Woolwich Crown Court last October after admitting 10 breaches of a High Court order made in 2021 (Jordan Pettitt/PA) News in 90 Seconds - 5th June 2025
RTÉ News
6 hours ago
- RTÉ News
Bitter pill: EU exploits Trump anti-science climate to forge deal on medicines
The EU's sweeping new rules on the regulation of medicines has been one of the most bitterly contested pieces of legislation in recent times, with fierce lobbying by the pharma sector - particularly in Ireland - and member states divided on which to prioritise: cheaper medicines for patients, or a regulatory environment that supports indigenous European manufacturers in the face of US dominance. After two years of deadlock, 26 member states have agreed on a compromise proposal, with only Malta - which has its own small-market medicines challenge - abstaining. Ironically, it was the Trump administration's hostility to science and medicine regulators that convinced EU member states that the moment to finally agree on a new set of rules was at hand. "In the US you have a chaotic situation," says one source familiar with negotiations, "between [Health Secretary] Robert Kennedy Jr, who doesn't believe in science or vaccines, and the Trump administration, which has sacked three and a half thousand people from the Food and Drugs Administration. "There was a sense in Europe that we should try to get this proposal settled so that we have a stable system in Europe when there's instability elsewhere." The legislation will now go to the European Parliament, where negotiations between MEPs, the member states and the European Commission, begin on 17 June. There are hopes that the entire package could be adopted by the end of the year. The European Commission first proposed overhauling the EU's medicines regime in April 2023, as Europe was emerging from the Covid pandemic. The EU was reeling from the strain the emergency put on health systems and on the availability of certain kinds of medicines, with a deepening awareness that Europe was overly dependent on China and India for drugs such as antibiotics. At the same time, digitalisation and the availability of clinical data were opening up new possibilities in how medicines are developed and used. Despite that, innovative therapies were not reaching patients across Europe at the same speed while in some member states patients did not have access to medicines they needed due to shortages. The instinct to reduce health spending further has been given fresh impetus by the expected surge in EU defence expenditure following Russia's invasion of Ukraine. Overall, the pharma package sought to boost the competitiveness of the sector, reduce the administrative burden - and the over-reliance on India and China - and to tackle the environmental impact of drug manufacture and use. The central, most divisive issue was around the protection that big European pharma countries would have in holding on to clinical data before generic manufacturers - who could produce cheaper drugs - could access it. It became a straightforward contest between the competing interests of big pharma, which argued that companies needed the protection in order to invest more in life-saving domestic European research and innovation, and those countries which were more interested in lowering the cost of medicines and making those medicines more accessible to patients. The legislation was always going to face a stormy passage. "The difficulty was that the countries that didn't have pharmaceutical industries were very much opposing the regulatory data protection (RDP) element because all they were interested in was making medicines available to citizens," says Fianna Fáil MEP Billy Kelleher, a substitute member of the European Parliament health committee. "Eastern European countries like Poland, Romania, Bulgaria and others would have been very, very reluctant to support the strong protection of regulatory data, while it was the old West, countries like Ireland, Belgium, Italy, Germany and the Netherlands that have big manufacturing and pharma centres, a lot of research and development, who were pushing for it." The new rules would attempt to reconcile the issue of regulatory data protection, which theoretically encourages pharmaceutical companies to invest more in life-saving medicines, with the need to make drugs more affordable. Under existing EU rules, pharma companies were entitled to keep clinical data for eight years - the so-called regulatory data protection (RDP) before they were obliged to make it accessible. After the eight years was up, generic producers could file an application to use the data, at which point the patent holder enjoyed a further two - and sometimes three - extra years of protection. Under the commission's 2023 proposal, there would be a two-year reduction in the baseline RDP to six years, with an extra two years of protection. However, pharma companies could claw back a further two years of protection - extending RDP to ten years. The ten-year protection period would be available if the patent holder won approval for significant new innovations (one extra year of protection), if the product addressed an "unmet medical need", ie, where there was product authorised in the EU for a particular disease, or where the disease was associated with a high death-rate (such a situation would merit an extra six months of market protection), or if the manufacturer conducted clinical trials or extended access to all member states (another six months). Essentially, the commission was attempting to balance the need to reward medicines that meet the greatest clinical need, while speeding up access to generic producers who will make drugs that are cheaper. However, the new rules were facing hostility from traditional pharma manufacturing countries such as Germany, France, Denmark and the Netherlands, who argued that a shorter clinical data protection period would stymie research. The Irish Times reported on a full scale lobbying effort by industry, including a claim in a letter to Tánaiste Simon Harris by the Irish Pharmaceutical Healthcare Association (IPHA) that the proposal could lead to a 22% drop in new medicines being developed over the coming decade. It is understood there were tensions between the IDA and Enterprise Ireland, who shared the concerns of industry, and the Department of Health, which was more concerned with lowering the cost of medicines and making them more accessible. A number of sources have said that while member states with important pharma sectors went public two years ago, when the commission first proposed reducing clinical data protection from eight years to six, in demanding the status quo of eight years, Ireland remained on the fence, and did so right up until a key meeting of EU ambassadors on 21 May. On that date, Ireland joined a blocking majority of ten countries - including Belgium, Denmark, the Netherlands and Germany - to oppose the latest Polish proposal that would have essentially increased the RDP by one year to seven, but short of eight. As a result of that blocking minority, the Poles came back with another compromise text, which is - to all intents and purposes - a return to eight years, with various caveats and conditions designed to make medicines cheaper and more accessible (one part of the text aims to ensure that medicinal products are available in all member states and provides for regulatory action if the marketing authorisation holder does not comply). Officials say the text provides more reassurance for generic producers, and will cut timelines for authorised medicines to get to market. There are other measures, including making it easier to have multi-country and multilingual medicine packs, which should reduce production costs and make it easier to move medicines around Europe. At yesterday morning's meeting of EU ambassadors, the new text received overwhelming support. The IPHA are understood to be broadly satisfied with the compromise. In a statement, the organisation said it "believes the [member states] position represents a more balanced approach than had originally been proposed by the Commission. "As the legislative process enters the final phase, EU decision makers must continue to find solutions that will keep Europe competitive through a predictable and globally competitive environment for research, development and manufacturing, while ensuring fairer access to innovative medicines for patients across the EU." Support is not uniform. The chief executive of the Confederation of Danish Industry Lars Sandahl Sørensen accused member states of triggering a potential flight of European industry to Trump's America. "We are de facto making the EU's pharmaceutical industry less competitive and thus European society vulnerable," he said. The European pharma lobby group EFPIA described yesterday's position by member states as "a missed opportunity to position Europe's life sciences sector at the forefront of global competition". In a statement, EFPIA said: "The choice to reduce intellectual property protections for pharmaceutical companies makes Europe less attractive, discouraging investment and jeopardising the development of innovative treatments in Europe without addressing the underlying barriers and delays to patient access." There is some scepticism over the industry's seeming exploitation of Donald Trump's persistence in threatening tariffs on European pharmaceutical exports and reshoring manufacturing to the US. In April the industry wrote to commission president Ursula von der Leyen, suggesting that €50.6 billion in capital investment and €52.6bn in research and development expenditure were at risk if the EU continued to over-regulate the pharma sector. "Unless Europe delivers rapid, radical policy change then pharmaceutical research, development and manufacturing is increasingly likely to be directed towards the US," EFPIA warned. Officials suggest the upcoming Critical Medicines Act (CMA) will further boost access to cheaper medicines. Drugs such as those for diabetes or HRT have been susceptible to disruption and shortages in recent years because they are often generic and produced outside the EU. The CMA will aim to encourage more manufacturing of such drugs in Europe. The action now moves to the European Parliament, where so-called trilogues - three way negotiations between member states, the Commission and MEPs - will further shape the legislation. Last year the parliament adopted its own position, calling for an RDP of seven and a half years with the possibility of some extensions. The parliament has since moved to the right, following last year's elections, so it remains to be seen if further battles are expected.
